The Union Health Ministry has issued an updated ''Clinical Guidance for Management of Adult COVID-19 Patients'' recommending emergency use authorisation of remdesivir for patients with moderate to severe diseases, requiring supplemental oxygen, within 10 days of onset of symptoms.

The guidelines issued by AIIMS, ICMR-COVID-19 National Task Force and the Joint Monitoring Group (DGHS) under the ministry stated that tocilizumab (a drug that modifies the immune system or its functioning) may be considered in patients with significantly raised inflammatory markers and not improving despite use of steroids with there being no active bacterial/fungal/tubercular infection.